Barker Colin M, Price Matthew J
Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA.
Curr Cardiol Rep. 2008 Jul;10(4):327-33. doi: 10.1007/s11886-008-0052-y.
Acute coronary syndromes (ACS), characterized by unstable angina or a non-ST-segment elevation myocardial infarction, are caused by rupture of an atherosclerotic plaque, leading to platelet activation and aggregation, thrombus formation, and microembolization. Antiplatelet therapy is a cornerstone of therapy. Combined with aspirin, clopidogrel provides significant benefit for patients across the ACS spectrum. However, clopidogrel has limitations given its slow onset and the inconsistent level of inhibition that it achieves. Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset of action and greater and more consistent platelet inhibition.
急性冠状动脉综合征（ACS）以不稳定型心绞痛或非ST段抬高型心肌梗死为特征，由动脉粥样硬化斑块破裂引起，导致血小板活化和聚集、血栓形成及微栓塞。抗血小板治疗是治疗的基石。与阿司匹林联合使用时，氯吡格雷对整个ACS谱系的患者都有显著益处。然而，氯吡格雷起效缓慢且抑制水平不一致，存在局限性。新型噻吩并吡啶类和非噻吩并吡啶类P2Y12受体激动剂具有起效迅速、血小板抑制作用更强且更一致的优点。
